Immune Thrombocytopenic Purpura Clinical Trial
Official title:
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by bleeding due to isolated thrombocytopenia with platelet count less than 100 × 109/L. ITP is classified based on course of disease into acute (3- <12 months), and chronic (≥12 months). ITP usually has a chronic course in adults whereas approximately 80-90% of children undergo spontaneous remission within weeks to months of disease onset. The main pathogenesis of ITP is the loss of immune tolerance to platelet auto-antigens, which results in increased platelet destruction and impaired thrombopoiesis by autoantibodies and cytotoxic T lymphocytes (CTLs). Platelet autoantibodies, particularly antiglycoprotein (GP) GPIIbIIIa and anti-GPIbIX, are known to cause thrombocytopenia in patients with ITP. As a main component of cellular immunity, T cells play an important role in body defense and peripheral tolerance. Changing number and function of these cells is closely associated with various diseases, including ITP.NK cells can also modulate cellular immunity in ITP patients.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 2022 |
Est. primary completion date | November 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 50 Years |
Eligibility | Inclusion Criteria: - Patients with platelet less than 100 × 109/L diagnosed as immune thrombocytopenia according to bone marrow findings . Exclusion Criteria: - Other causes of thrombocytopenia as: - Hypersplenism. - Bone marrow diseases including : aplastic anemia, leukemia and myelodysplastic syndromes. - Cancer treatments like chemotherapy and radiation therapy. - Exposure to toxic chemicals as arsenic and benzene. - Medications to treat bacterial infections (antibiotics)and treat seizures or blood thinner heparin. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sohag University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment the percentages of CD4+ cells from peripheral blood samples by Flowcytometry | Methods of the study: All patients were subjected to:
Full history taking. Laboratory investigations: Complete blood picture . Erythrocyte sedimentation rate(ESR). Liver function tests . Kidney function tests. Anti-nuclear antibodies test by immunofluorescence for ITP patients. Bone marrow aspiration (for diagnosis of ITP). CD3, CD4 from peripheral blood samples by Flowcytometry. |
within 3 days after collection of samples. | |
Primary | Assessment the percentages of CD8+cells in ITP patients from peripheral blood samples by Flowcytometry . | Methods of the study: All patients were subjected to:
Full history taking. Laboratory investigations: Complete blood picture . Erythrocyte sedimentation rate(ESR). Liver function tests . Kidney function tests. Anti-nuclear antibodies test by immunofluorescence for ITP patients. Bone marrow aspiration (for diagnosis of ITP). CD3, CD8 from peripheral blood samples by Flowcytometry. |
within 3 days after collection of samples. | |
Primary | Assessment the percentages of NK(CD16 +, CD56 +) cells in ITP patients from peripheral blood samples by Flowcytometry . | Methods of the study: All patients were subjected to:
Full history taking. Laboratory investigations: Complete blood picture . Erythrocyte sedimentation rate(ESR). Liver function tests . Kidney function tests. Anti-nuclear antibodies test by immunofluorescence for ITP patients. Bone marrow aspiration (for diagnosis of ITP). CD16, CD56 from peripheral blood samples by Flowcytometry. |
within 3 days after collection of samples. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01255332 -
Helicobacter Pylori Immune Thrombocytopenic Purpura
|
Phase 2 | |
Completed |
NCT02077192 -
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
Completed |
NCT01621204 -
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
|
Phase 3 | |
Completed |
NCT01719692 -
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
|
N/A | |
Completed |
NCT01730352 -
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01713855 -
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
|
N/A | |
Completed |
NCT01390649 -
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 4 | |
Completed |
NCT01672151 -
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
|
N/A | |
Completed |
NCT01439321 -
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
|
N/A | |
Completed |
NCT00774202 -
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
|
Phase 2/Phase 3 | |
Completed |
NCT02273960 -
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05585944 -
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
|
N/A | |
Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
Not yet recruiting |
NCT05835050 -
Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital
|
N/A | |
Active, not recruiting |
NCT03395210 -
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
|
Phase 2 | |
Completed |
NCT00621894 -
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
|
Phase 2 | |
Not yet recruiting |
NCT06444477 -
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
|
||
Completed |
NCT01652599 -
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
|
Phase 2 | |
Completed |
NCT00426270 -
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
|
Phase 3 | |
Completed |
NCT02085993 -
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
|
N/A |